OMEGAPHARM CEFTAZIDIME FOR INJECTION ceftazidime (as pentahydrate) 2g powder for injection vial

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

ceftazidime pentahydrate, Quantity: 2349 mg (Equivalent: ceftazidime, Qty 2000 mg)

Available from:

Omegapharm

INN (International Name):

ceftazidime pentahydrate

Pharmaceutical form:

Injection, powder for

Composition:

Excipient Ingredients: sodium carbonate

Administration route:

Intravenous

Units in package:

5 vials, 1 vial

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

OMEGAPHARM CEFTAZIDIME FOR INJECTION is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime; as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antipseudomonal antibiotics cannot be used. . Indications include the following.. Severe infections in general. For example: septicaemia (including neonatal sepsis), bacteraemia; in patients in intensive care units with specific problems, e.g. infected burns.. Respiratory tract. For example: pneumonia, bronchopneumonia, infected pleurisy, infected bronchiectasis and bronchitis.. Severe ear, nose and throat infections. For example: otitis media, mastoiditis.. Urinary tract. For example: acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only); infections associated with bladder and renal stones.. Skin and soft tissue. . For e

Product summary:

Visual Identification: White or cream coloured powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 12 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Authorization status:

Registered

Authorization date:

2010-10-19